Cancer Immunology, Immunotherapy

, Volume 27, Issue 2, pp 154–162 | Cite as

Immunohistochemical monitoring of metastatic colorectal carcinoma in patients treated with monoclonal antibodies (MAb 17-1A)

  • Jayant Shetye
  • Jan-Erik Frödin
  • Birger Christensson
  • Crawford Grant
  • Björn Jacobsson
  • Staffan Sundelius
  • Mikael Sylvén
  • Peter Biberfeld
  • H»kan Mellstedt
Original Articles


A therapeutic trial using repeated doses of a mouse monoclonal antibody against the tumor-associated antigen (TAA) CO17-1A in metastatic colorectal carcinomas was carried out. Metastatic lesions sampled by repeated thick needle (1.2 mm) biopsies during therapy were examined immunohistochemically for the presence of various TAAs, mouse IgG, complement, and infiltrating leukocytes. The CO17-1A was consistently expressed in all cases along the basement membrane of tumor glands and could only be demonstrated on cryostat sections whereas the TAAs GICA19-9, GA73-3, and Br55-2 were also visualized in B5-fixed paraffin-embedded biopsies. The CO17-1A and GA73-3 were predominantly present at the basal region in contrast to the GICA 19-9 and Br55-2 which were predominant at the luminal and the apical region of the tumor glands. Antigenic modulation was not seen either after 24–72 h or during prolonged treatment. In all cases the infused mouse IgG was detected, from 24 h after infusion up to 6–8 weeks, mainly along the basal region of tumor glands. In 13/14 posttreatment biopsies, complement factor C3 was found at the same sites as mouse IgG. In 6 out of 9 posttreatment biopsies an increase in mononuclear cells (monocytes, natural killer (NK) cells and/or T cells) was observed. Monocytes were close to the tumor cells whereas NK cells and T cells were predominantly scattered in the stroma.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Adams DO, Hall T, Steplewski Z, Koprowski H (1984) Tumors undergoing rejection induced by monoclonal antibodies of the IgG2a isotype contain increased numbers of macrophages activated for a distinctive form of antibody-dependent cytolysis. Proc Natl Acad Sci 81:3506Google Scholar
  2. 2.
    Bedikian AY, Chen TT, Malahy MA, Patt YZ, Bodey GP (1984) Prognostic factors influencing survival of patients with advanced colorectal cancer: Hepatic artery infusion versus systemic intravenous chemotherapy for liver metastases. J Clin Oncol 2:174Google Scholar
  3. 3.
    Bergmark S, Hagfström LO (1969) The natural history of primary and secondary malignant tumors of the liver. I. The prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy. Cancer 23:198Google Scholar
  4. 4.
    Dawson PM, Habib NA, Peck M, Blaxland JW, Luck RJ (1986) Patient survival with liver metastases from colorectal cancer — a district hospital experience. Eur J Surg Oncol 12:131Google Scholar
  5. 5.
    Douillard JY, Lehur PA, Vignoud J, Blottiere H, Maurel C, Thedrez P, Kremer M, Le Mevel B (1986) Monoclonal antibodies specific immunotherapy of gastro-intestinal tumors. Hybridoma 5 (suppl I):139Google Scholar
  6. 6.
    Dukes CE, Bussey HJR (1958) The spread of rectal cancer and its effects on prognosis. Br J Cancer 12:309Google Scholar
  7. 7.
    Ekberg H, Tranberg KG, Lundstedt C, Hahff G, Ranstam J, Jeppsson B, Bengmark S (1986) Determinants of survival after intraarterial infusion of 5-fluorouracil for liver metastases from colorectal cancer: A multivariate analysis. J Surg Oncol 31:246Google Scholar
  8. 8.
    Frödin JE, Biberfeld P, Christensson B, Philstedt P, Sundelius S, Sylvén M, Wahren B, Koprowski H, Mellstedt H (1986) Treatment of patients with metastasizing colo-rectal carcinoma with mouse monoclonal antibodies (MOAb17–1A). A progress report. Hybridoma 5 (suppl I):151Google Scholar
  9. 9.
    Garcia CF, Lowder J, Meeker TC, Bindl J, Levy R, Warnke RA (1985) Differences in “host infiltrates” among lymphoma patients treated with anti-idiotype antibodies: correlation with treatment response. J Immunol 135:4252Google Scholar
  10. 10.
    Goslin R, Steele Jr G, Zamcheck N, Mayer R, MacIntyre J (1982) Factors influencing survival in patients with hepatic metastases from adenocarcinoma of the colon or rectum. Dis Colon Rectum 25:749PubMedGoogle Scholar
  11. 11.
    Herlyn DM, Koprowski H (1982) IgG2A monoclonal antibodies inhibit human tumor growth through interaction with effector cells. Proc Natl Acad Sci 79:4761Google Scholar
  12. 12.
    Herlyn DM, Herlyn MF, Steplewski Z, Koprowski H (1979) Monoclonal antibodies in cell-mediated cytotoxicity against human melanoma and colo-rectal carcinoma. Eur J Immunol 9:657Google Scholar
  13. 13.
    Herlyn DM, Herlyn MF, Ross AH, Ernst C, Atkinson B, Koprowski H (1984) Efficient selection of human tumor growth-inhibiting monoclonal antibodies. J Immunol Methods 73:157Google Scholar
  14. 14.
    Herlyn MF, Steplewski Z, Herlyn DM, Koprowski H (1986) CO17–1A and related monoclonal antibodies: Their production and characterization. Hybridoma 5 (suppl I):3Google Scholar
  15. 15.
    Hsu SM, Raine L, Fanger H (1981) Use of avidin-biotin-peroxidase Complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabelled antibody (PAP) procedures. J Histochem Cytochem 29:577PubMedGoogle Scholar
  16. 16.
    Magnani JL, Nilson B, Brockhaus M, Zopf D, Steplewski Z, Koprowski H, Ginsburg V (1982) A monoclonal antibody defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II. J Biol Chem 257:14365Google Scholar
  17. 17.
    Mason DY, Bell JJ, Christensson B, Biberfeld P (1980) An immunohistological study of human lymphoma. Clin Exp Immunol 40:235Google Scholar
  18. 18.
    Mellstedt H, Frödin J-E, Christensson B, Shetye J, Biberfeld P, Lefvert A-K, Pihlstedt P, Sylvén M, Makower J, Wahren B, Ahlman B, Cedermark B, Erwald R, Klingenström P, Nathansson J, Rieger A, Koprowski H (1988) Application of monoclonal antibodies (MAb 17–1A) in the treatment of colorectal carcinomas: In: Carrano RA, Douillard JY (eds) Monoclonal antibodies in clinical oncology. Marcel Dekker, New York (in press)Google Scholar
  19. 19.
    Mellstedt H, Frödin J-E, Masucci G, Lindemalm C, Wedelin C, Christensson B, Shetye J, Biberfeld P, Lefvert A-K, Pihlstedt P, Makower J, Harmenberg U, Wahren B, Ahlman B, Cedermark B, Erwald R, Magnusson I, Nathansson J, Rieger A (1988) MAb 17–1A used for therapy of patients with metastatic colorectal carcinomas. In: Beger HG, Reisfeld R (eds) New approaches in cancer treatment. Springer-Verlag, Berlin (in press)Google Scholar
  20. 20.
    Neville AM, Gusterson BA (1985) Monoclonal antibodies and human tumors; pathological and clinical aspects. Eur J Cancer Clin Oncol 21:355Google Scholar
  21. 21.
    Porwit-Ksiazek A, Ksiazek T, Biberfeld P (1983) Leu-7+ (HNK-1+) cells. I. Selective compartmentalisation of Leu-7+ cells with different immunophenotypes in lymphatic tissues and blood. Scand J Immunol 18:485Google Scholar
  22. 22.
    Ross AH, Herlyn D, Diopoulos D, Koprowski H (1986) Isolation and characterization of a carcinoma-associated antigen. Biochem Biophys Res Commun 135:297Google Scholar
  23. 23.
    Schulz G, Staffileno LK, Reisfeld RA, Dennert G (1985) Eradication of established human melanoma tumor in nude mice by antibody-directed effector cells. J Exp Med 161:1315Google Scholar
  24. 24.
    Sears HF, Mattis J, Herlyn DM, Häyry P, Atkinson B, Ernst C, Steplewski Z, Koprowski H (1982) Phase I clinical trial of monoclonal antibody in treatment of gastro-intestinal tumors. Lancet I:762Google Scholar
  25. 25.
    Sears HF, Herlyn DM, Häyry P, Atkinson B, Ernst C, Steplewski Z, Koprowski H (1985) Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastro-intestinal adenocarcinoma. Cancer Res 45:5910Google Scholar
  26. 26.
    Sears HF, Herlyn DM, Steplewski Z, Koprowski H (1986) Initial trial use of murine monoclonal antibodies as immunotherapeutic agents for gastro-intestinal adenocarcinoma. Hybridoma 5 (suppl I):109Google Scholar
  27. 27.
    Shen JW, Atkinson B, Koprowski H, Sears HF (1984) Binding of murine immunoglobulin to human tissues after immunotherapy with anti-colo-rectal carcinoma monoclonal antibody. Int J Cancer 33:465Google Scholar
  28. 28.
    Sindelar WF, Maher MM, Herlyn D, Sears HF, Steplewski Z, Koprowski H (1986) Trial of therapy with monoclonal antibody 17–1A in pancreatic carcinoma. Preliminary results. Hybridoma 5 (suppl I):125Google Scholar
  29. 29.
    Steplewski Z, Herlyn D, Lubeck M, Kimoto Y, Herlyn M, Koprowski H (1986) Mechanisms of tumor growth inhibition. Hybridoma 5 (suppl I):59Google Scholar
  30. 30.
    Tempero MA, Pour PM, Uchida E, Herlyn D, Steplewski Z (1986) Monoclonal antibody CO17–1A and leukapheresis in immunotherapy of pancreatic cancer. Hybridoma 5 (suppl I):133Google Scholar
  31. 31.
    Blaszczyk-Thurin M, Thurin J, Hindsgaul O, Karlsson KA, Steplewski Z, Koprowski H (1987) Y and blood group B type 2 glycolipid antigens accumulate in a human gastric carcinoma cell line as detected by monoclonal antibody: Isolation and characterization by mass spectrometry and NMR spectroscopy. J Biol Chem 262(1):372Google Scholar
  32. 32.
    Verrill H, Goldberg M, Rosenbaum R, Abbott R, Simunovic L, Steplewski Z, Koprowski H (1986) Clinical trial of Wistar Institute 17–1A monoclonal antibody in patients with advanced gastro-intestinal adenocarcinoma. A preliminary report. Hybridoma 5 (suppl I):175Google Scholar

Copyright information

© Springer-Verlag 1988

Authors and Affiliations

  • Jayant Shetye
    • 1
    • 2
  • Jan-Erik Frödin
    • 2
  • Birger Christensson
    • 1
  • Crawford Grant
    • 1
  • Björn Jacobsson
    • 1
  • Staffan Sundelius
    • 3
  • Mikael Sylvén
    • 3
  • Peter Biberfeld
    • 1
  • H»kan Mellstedt
    • 2
  1. 1.Department of PathologyKarolinska Institute and HospitalStockholmSweden
  2. 2.Department of Oncology and Immunology Research Laboratory, RadiumhemmetKarolinska Institute and HospitalStockholmSweden
  3. 3.Department of Diagnostic RadiologyKarolinska Institute and HospitalStockholmSweden

Personalised recommendations